SUBSTANCE DEPENDENT TEENS--IMPACT OF TREATING DEPRESSION

物质依赖青少年——治疗抑郁症的影响

• 批准号: 6646416
• 负责人: Paula DeGraffenreid Riggs
• 金额: $ 65.75万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-30 至 2005-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6646416
• 关键词: adolescence (12-20); behavioral /social science research tag; clinical research; clinical trials; cognitive behavior therapy; combination therapy; comorbidity; conduct disorder; fluoxetine; human subject; human therapy evaluation; major depression; mental disorder chemotherapy; substance abuse related disorder; therapy compliance

DESCRIPTION: (Applicant's Abstract) Adolescents with substance use disorders (SUD) and conduct disorder (CD) have high rates of comorbid depression. Despite the high prevalence of depression in such youth, little is known about effective treatment of such depressions. Moreover, the effects of treating depression on substance use and other problem behaviors in such youth are not known. Only serotonergic agents, fluoxetine (FLX) and paroxetine, with most support for FLX, have empirical support in the treatment of depression in adolescents without serious comorbidity. It is not known whether FLX (or paroxetine) are effective in treating the depressions of adolescents with SUD and CD. The proposed study is a randomized, placebo-controlled trial comparing placebo to fluoxetine for major depressive disorder (MDD) in 120 adolescents with SUD and CD. Adolescents with DSM-1V SUD, CD, and MDD assessed both clinically and with structured assessment instruments, will be randomized to one of these two treatment cells for 16 weeks. All subjects will also receive standardized, manual-driven cognitive behavior treatment for adolescent SUD for the duration of the trial as the background "treatment as usual" Medication compliance will be electronically monitored. Adverse side effects will be monitored weekly. The specific aims of this study are to test the following hypotheses: 1. Fidoxeline + CBT will be more effective in treating unipolar depression in adolescents with SUD and CD than placebo + CBT. 2. The treatment of depression with RX + CBT, in depressed adolescents with SUD and CD will be more effective than placebo + CBT in reducing substance use and improving conduct symptoms. 3. The treatment of depression with RX will result in greater retention in, and compliance with substance treatment (CBT) and reduction in both substance use and conduct problems than treatment with placebo. This research will contribute important knowledge regarding effective treatment of depression in conduct-disordered adolescents with SUD and provide information about the effects of treating depression on substance and other behavioral outcomes as well.

描述：（申请人的摘要） 患有药物使用障碍的青少年（SUD）和行为障碍（CD） 合并抑郁症的高率。尽管抑郁症患病率很高 这样的年轻人对这种沮丧的有效治疗知之甚少。 此外，治疗抑郁症对药物使用和其他问题的影响 这些年轻人的行为尚不清楚。只有血清素能剂，氟西汀 （FLX）和Paroxetine，对FLX的最大支持，在 没有严重合并症的青少年抑郁症的治疗。它不是 知道FLX（或Paroxetine）是否有效治疗 有SUD和CD的青少年。拟议的研究是一项随机的， 安慰剂对照试验将安慰剂与氟西汀进行比较 120名具有SUD和CD的青少年中的疾病（MDD）。具有DSM-1V SUD的青少年， CD和MDD通过临床和结构化评估进行了评估 仪器将被随机分为这两个治疗单元之一的16 几周。所有受试者还将获得标准化的，手动驱动的认知 在试验期间，青少年SUD的行为处理 背景“照常治疗”的药物合规性将以电子方式为电子 受监控。不良副作用将每周监控。具体目的 这项研究是测试以下假设：1。Didoxeline + CBT将是 在SUD和CD的青少年治疗单极抑郁症方面更有效 比安慰剂 + CBT。 2。用RX + CBT治疗抑郁症，抑郁症 具有SUD和CD的青少年比安慰剂 + CBT更有效 减少药物使用并改善行为症状。 3。 RX的抑郁将导致更大的保留率，并符合 药物治疗（CBT）和药物使用和进行的减少 问题比安慰剂治疗。这项研究将有助于重要 关于有效治疗抑郁症的知识 具有SUD的青少年，并提供有关治疗影响的信息 抑郁症以及其他行为结果。